Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Time-to-progression in breast cancer: a stratification model for clinical trials.

de la Haba-Rodríguez J, Aranda E, Llombart A, Lluch A, Alba E, Munárriz B, Adrover E, Tusquets I, Balil A, Barnadas A, Calvo L, Martín M; Grupo Español de Investigación en Cáncer de Mama (GEICAM).

Breast. 2008 Jun;17(3):239-44. Epub 2007 Nov 26.

PMID:
18042386
2.

Factors affecting survival in breast cancer patients following bone metastasis.

Yavas O, Hayran M, Ozisik Y.

Tumori. 2007 Nov-Dec;93(6):580-6.

3.

Survival impact of integrative cancer care in advanced metastatic breast cancer.

Block KI, Gyllenhaal C, Tripathy D, Freels S, Mead MN, Block PB, Steinmann WC, Newman RA, Shoham J.

Breast J. 2009 Jul-Aug;15(4):357-66. doi: 10.1111/j.1524-4741.2009.00739.x. Epub 2009 May 12.

PMID:
19470134
4.

Disease-free survival and prognostic significance of metastatic lymph node ratio in T1-T2 N positive breast cancer patients. A population registry-based study in a European country.

Martinez-Ramos D, Escrig-Sos J, Alcalde-Sanchez M, Torrella-Ramos A, Salvador-Sanchis JL.

World J Surg. 2009 Aug;33(8):1659-64. doi: 10.1007/s00268-009-0078-3.

PMID:
19488815
5.

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial.

Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, Lebrecht A, Siggelkow W, Hengstler JG, Elsässer A, Gehrmann M, Lehr HA, Koelbl H, von Minckwitz G, Harbeck N, Thomssen C.

Ann Oncol. 2009 Feb;20(2):258-64. doi: 10.1093/annonc/mdn590. Epub 2008 Sep 29.

6.

Prognostic scores in brain metastases from breast cancer.

Nieder C, Marienhagen K, Astner ST, Molls M.

BMC Cancer. 2009 Apr 7;9:105. doi: 10.1186/1471-2407-9-105.

7.

Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.

Pentheroudakis G, Fountzilas G, Kalofonos HP, Golfinopoulos V, Aravantinos G, Bafaloukos D, Papakostas P, Pectasides D, Christodoulou C, Syrigos K, Economopoulos T, Pavlidis N; Hellenic Cooperative Oncology Group.

Crit Rev Oncol Hematol. 2008 Jun;66(3):237-47. doi: 10.1016/j.critrevonc.2007.12.003. Epub 2008 Feb 1.

PMID:
18243010
8.

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.

J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. doi: 10.1093/jnci/djn309. Epub 2008 Sep 23.

9.

Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.

Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, Chambers AF.

Breast Cancer Res Treat. 2009 Apr;114(3):503-11. doi: 10.1007/s10549-008-0033-2. Epub 2008 Apr 25.

PMID:
18437556
10.

Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?

Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, Jackson S, Hortobagyi GN, Fritsche H, Cristofanilli M.

Cancer. 2008 Nov 1;113(9):2422-30. doi: 10.1002/cncr.23852.

11.

A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.

Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M.

Breast Cancer Res. 2008;10(5):R74. doi: 10.1186/bcr2139. Epub 2008 Sep 4.

12.

Prognostic factors for survival in breast cancer patients who developed distant metastasis subsequent to definitive surgery.

Kuru B, Camlibel M, Dinc S, Gulcelik MA, Gonullu D, Alagol H.

Singapore Med J. 2008 Nov;49(11):904-11.

13.

A scoring system to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a comparison with other scoring systems.

Cho J, Han W, Lee JW, Ko E, Kang SY, Jung SY, Kim EK, Moon WK, Cho N, Park IA, Chung JK, Hwang KT, Kim SW, Noh DY.

Ann Surg Oncol. 2008 Aug;15(8):2278-86. doi: 10.1245/s10434-008-9993-z. Epub 2008 Jun 5.

PMID:
18528729
14.

Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.

Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J; Danish Breast Cancer Cooperative Group.

J Clin Oncol. 2008 Mar 20;26(9):1419-26. doi: 10.1200/JCO.2007.14.5565. Epub 2008 Feb 19.

15.

Predicting distant dissemination in patients with early breast cancer.

Arriagada R, Rutqvist LE, Johansson H, Kramar A, Rotstein S.

Acta Oncol. 2008;47(6):1113-21. doi: 10.1080/02841860701829661.

PMID:
18607866
16.

Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.

Lipton A, Leitzel K, Chaudri-Ross HA, Evans DB, Ali SM, Demers L, Hamer P, Brown-Shimer S, Pierce K, Gaur V, Carney W.

J Clin Oncol. 2008 Jun 1;26(16):2653-8. doi: 10.1200/JCO.2007.15.4336. Epub 2008 Apr 28.

17.

Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.

Loya A, Guray M, Hennessy BT, Middleton LP, Buchholz TA, Valero V, Sahin AA.

Cancer. 2009 Apr 15;115(8):1605-12. doi: 10.1002/cncr.24173.

18.

Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.

Er O, Frye DK, Kau SW, Broglio K, Valero V, Hortobagyi GN, Arun B.

Cancer J. 2008 Jan-Feb;14(1):62-8. doi: 10.1097/PPO.0b013e3181629a7b.

PMID:
18303485
19.

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.

Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM.

Breast Cancer Res Treat. 2009 Jan;113(2):275-83. doi: 10.1007/s10549-008-9939-y. Epub 2008 Mar 4.

PMID:
18311582
20.

Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.

Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG.

Ann Surg. 2008 Jan;247(1):125-35.

PMID:
18156932
Items per page

Supplemental Content

Write to the Help Desk